Preview

Медицинский алфавит

Расширенный поиск

Сепсис и острое повреждение почек — дорога с двухсторонним движением: значения биомаркеров. Часть II

https://doi.org/10.33667/2078-5631-2019-3-22(397)-48-55

Полный текст:

Аннотация

Краткий обзор, посвященный септическому острому повреждению почек (С-ОПП), синдрому, одновременно соответствующему критериям сепсиса и ОПП. Согласно статистике, у 30–50 % критических пациентов диагностируется или сепсис, или ОПП, при этом сепсис стимулирует развитие ОПП, а развитие ОПП — сепсис. Морбидность и летальность при С-ОПП выше, чем при сепсисе и ОПП по отдельности. Основные патофизиологические механизмы: а) развития ОПП при сепсисе: поступающая в почки «токсичная септическая» кровь содержит большое количество провоспалительных факторов, что повреждает канальцы и приводит к тубулярной дисфункции; б) развития сепсиса при ОПП: ОПП повреждает дистальные органы, а уремия — функции иммунной системы, что провоцирует развитие сепсиса. Для ранней диагностики и мониторинга С-ОПП должны проводиться параллельное измерение и мониторинг маркеров сепсиса и ренальной дисфункции. Однако, как показывают многочисленные данные, наличие ОПП приводит к неинфекционному повышению маркеров сепсиса, а наличие сепсиса повышает маркеры ОПП независимо от ренальной дисфункции. В целом при сепсисе ОПП и С-ОПП ренальные маркеры одновременно отражают как тяжесть ренальной дисфункции, так и тяжесть воспаления, а маркеры сепсиса — как тяжесть сепсиса, так и тяжесть ренальной дисфункции. Для определения пограничных уровней септических маркеров, применяемых для диагностики С-ОПП, необходимы рекомендации по повышению их значений в зависимости от степени тяжести ренальной дисфункции у критических пациентов.

Об авторе

В. В. Вельков
АО «ДИАКОН»
Россия

к. б. н., директор по науке

г. Пущино, Московская область



Список литературы

1. Stuveling EM, Hillege HL, Bakker SJ, et al. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003; 63: 654–661.

2. Pecoits-Filho R, Sylvestre LC, Stenvinkel P. Chronic kidney disease and inflammation in pediatric patients: from bench to playground. Pediatr Nephrol 2005; 20: 714–720.

3. Rabb H, Griffin MD, McKay DB, et al. Acute Dialysis Quality Initiative Consensus XIII Work Group: Inflammation in AKI: Current Understanding, Key Questions, and Knowledge Gaps. J Am Soc Nephrol. 2015.

4. Vashist SK, Venkatesh AG, Marion Schneider E et al. Bioanalytical advances in assays for C-reactive protein Biotechnol Adv. 2016; 34 (3): 272–90.

5. R. Thiele,1 J. Zeller,1 H. Bannasch,1 et al. Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes. Mediators of Inflammation Volume 2015, Article ID 372432.

6. Sproston NR and Ashworth JJ. Role of C-Reactive Protein at Sites of Inflammation and Infection. Front. Immunol. 2018 9: 754.

7. McFadyen JD, Kiefer J, Braig D, et al. Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation: Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes. Front. Immunol. 2018; 9: 1351.

8. Zhang L, Li HY, Li W, et al. An ELISA Assay for Quantifying Monomeric C-Reactive Protein in Plasma. Front Immunol. 2018, 12; 9: 511.

9. Li ZI, Chung AC, Zhou L, et al. C-reactive protein promotes acute renal inflammation and fibrosis in unilateral ureteral obstructive nephropathy in mice. Lab Invest. 2011; 91: 837–851.

10. Pegues MA, McCrory MA, Zarjou A, et al. C-reactive protein exacerbates renal ischemia-reperfusion injury. Am J Renal Physiol.2013, 304: F1358–F1365.

11. Jabs WJ, Lögering BA, Gerke P, et al. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol. 2003; 33 (1): 152–61.

12. Lai W, Tang Y, Huang XR et al. C-reactive protein promotes acute kidney injury by impairing tubular epithelial cell regeneration via the CD 32-Smad3-p27 dependent inhibition of CDK2/cyclin E mechanism. Kidney Int. 2016 90 (3): 610–626.

13. Schwedler SB, Guderian F, Dammrich J et al. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant 18: 2300–2307, 2003.

14. Gilbert DN. Role of Procalcitonin in the Management of Infected Patients in the Intensive Care. Infect Dis Clin N Am 31, 2017; 435–453.

15. Meisner M, Schmidt J, Hüttner H et al. The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med. 2000; 26 Suppl 2: 212-6.

16. Dahaba AA, Rehak PH, List WF. Procacitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Inten Care Med 2003; 29: 579-83.

17. Contou D, d’Ythurbide G, Messika J et al. Description and predictive factors of infection in patients with chronic kidney disease admitted to the critical care unit J infect, 2014; 68 (2): 105–15.

18. Lu XL, Xiao ZH, Yang M et al. Diagnostic value of serum procalcitonin in patients with chronic renal insufficiency: a systematic review and meta-analysis. Nephrol Dial Transplant. 2013; 28: 122–129.

19. Sun Y, Jiang L, Shao X. Predictive value of procalcitonin for diagnosis of infections in patients with chronic kidney disease: a comparison with traditional inflammatory markers C-reactive protein, white blood cell count, and neutrophil pecentage Int Urol Nephrol. Int Urol Nephrol. 2017; 49 (12): 2205–2216.

20. Park JH, Kim DH, Jang HR et al. Clinical relevance of procalcitonin and C-reactive protein as infection markers in renal impairment: a cross-sectional study. Critical Care 2014 18: 640.

21. El-Sayed D, Grotts J, Golgert WA, et al. Sensitivity and Specificity of Procalcitonin in Predicting Bacterial Infections in Patients With Renal Impairment. Open Forum Infect Dis. 2014; 21; 1 (2): ofu068.

22. Lee WS, Kang DW, Back JH et al Cutoff value of serum procalcitonin as a diagnostic biomarker of infection in end-stage renal disease patients Korean J Intern Med. 2015; 30 (2): 198–204.

23. Nakamura Y, Murai A, Mizunuma M, et al. Potential use of procalcitonin as biomarker for bacterial sepsis in patients with or without acute kidney injury. J Infect Chemother. 2015; 21 (4): 257–63.

24. Takahashi G, Shibata S, Fukui Y et al. Diagnostic accuracy of procalcitonin and presepsin for infectious disease in patients with acute kidney injury. Diagn Microbiol Infect Dis. 2016; 86 (2): 205–10.

25. Nie X, Wu B, He Y et al. Serum procalcitonin predicts development of acute kidney injury in patients with suspected infection. Clin Chem Lab Med 2013; 51 (8): 1655–1661. Jeeha R, Skinner DL, De Vasconcellos K et al.,

26. Serum procalcitonin levels predict acute kidney injury in critically ill patients. Nephrology (Carlton), 2017 Oct 2.

27. Ammori BJ, Becker KL, Kite P, et al. Calcitonin precursors: early markers of gut barrier dysfunction in patients with acute pancreatitis. Pancreas. 2003; 27: 239–243.

28. Huang H-L, Nie X, Cai B, et al. Procalcitonin Levels Predict Acute Kidney Injury and Prognosis in Acute Pancreatitis: A Prospective Study. PLoS ONE, 2013 8 (12).

29. Kurtul A, Murat SN, Yarlioglues M et al., Procalcitonin as an Early Predictor of Contrast-Induced Acute Kidney Injury in Patients With Acute Coronary Syndromes Who Underwent Percutaneous Coronary Intervention Angiology, 2015, 1–7.

30. Heredia-Rodríguez M, Bustamante-Munguira J, Fierro I et al. Procalcitonin Cannot Be Used as a Biomarker of Infection in Heart-Surgery Patients with Acute Kidney Injury, J Crit Care. 2016; 33: 233–9.

31. Chenevier-Gobeaux C, Borderie D, Weiss N et al. Presepsin (sCD 14-ST), an innate immune response marker in sepsis. Clin Chim Acta. 2015; 450: 97–103.

32. Liu Y, Hou JH, Li Q, et al. Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and metaanalysis. Springerplus. 2016; 5 (1): 2091.

33. Wu CC, Lan HM, Han ST et al. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systematic review and meta-analysis Ann Intensive Care. 2017; 6; 7 (1): 91.

34. Yang HS, Hur M, Yi A., et al. Prognostic value of presepsin in adult patients with sepsis: Systematic review and meta-analysis PLoS One. 2018; 13 (1): e0191486.

35. Bellos I, Fitrou G, Pergialiotis V et al. The diagnostic accuracy of presepsin in neonatal sepsis: a meta-analysis. Eur J Pediatr. 2018; 177 (5): 625–632.

36. www.presepsintets.ru, сайт в Интернете.

37. Shozushima T, Takahashi G, Matsumoto N, et al. Usefulness of presepsin (sCD 14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother. 2011; 17: 764–9.

38. Nagata T, Yasuda Y, Ando M, et al. (2015) Clinical Impact of Kidney Function on Presepsin Levels. PLoS One. 2015; 10 (6): e0129159.

39. Nakamura Y, Ishikura H, Nishida T et al. Usefulness of presepsin in the diagnosis of sepsis in patients with or without acute kidney injury. BMC Anesthesiology BMC Anesthesiol. 2014; Oct 4; 14: 88 14: 88.

40. Saito J, Hashiba E, Kushikata T et al. Changes in presepsin concentrations in surgical patients with end-stage kidney disease undergoing living kidney transplantation: a pilot study. J Anesth. 2016; 30 (1): 174–7.

41. Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference. J Hepatol 2014 Jun; 60 (6): 1310–24.

42. Elefsiniotis I, Tsakiris SA, Barla G et al., Presepsin levels in cirrhotic patients with bacterial infections and/or portal hypertension-related bleeding, presenting with or without acute kidney injury. Annals of Gastroenterology. 2018. 31, 1–9.


Для цитирования:


Вельков В.В. Сепсис и острое повреждение почек — дорога с двухсторонним движением: значения биомаркеров. Часть II. Медицинский алфавит. 2019;3(22):48-55. https://doi.org/10.33667/2078-5631-2019-3-22(397)-48-55

For citation:


Velkov V.V. Sepsis and acute kidney injury as two-way street: values of biomarkers. Medical alphabet. 2019;3(22):48-55. (In Russ.) https://doi.org/10.33667/2078-5631-2019-3-22(397)-48-55

Просмотров: 125


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2078-5631 (Print)